2,911 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,911 shares of the company’s stock, valued at approximately $575,000.

A number of other hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Zoetis in the fourth quarter valued at $745,861,000. Morgan Stanley raised its stake in shares of Zoetis by 34.6% in the fourth quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after acquiring an additional 2,796,694 shares during the period. Moneta Group Investment Advisors LLC grew its holdings in shares of Zoetis by 124,281.9% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock worth $341,778,000 after purchasing an additional 2,330,285 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Zoetis by 171.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after purchasing an additional 2,102,306 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. bought a new position in shares of Zoetis in the third quarter worth about $176,219,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock traded up $0.70 during midday trading on Thursday, hitting $169.21. The company had a trading volume of 3,345,510 shares, compared to its average volume of 2,738,915. The stock has a market cap of $77.48 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.53 and a beta of 0.87. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The company has a fifty day simple moving average of $186.36 and a 200 day simple moving average of $182.34. Zoetis Inc. has a 12-month low of $151.03 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 earnings per share. As a group, analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 34.12%.

Analysts Set New Price Targets

A number of research firms have recently commented on ZTS. The Goldman Sachs Group upped their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler upped their price target on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. Stifel Nicolaus increased their target price on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, January 12th. Finally, StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $224.33.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.